医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Patent Expiries Will Pave the Way for the Generic Drugs Market in Japan: TechNavio

2015年02月10日 AM02:15
このエントリーをはてなブックマークに追加


 

LONDON

The Generic Drugs Market in Japan is expected to grow at a CAGR of 8.16 percent from 2014-2019, says research firm TechNavio.

About the Report

According to the latest report by TechNavio, the patents of many first-generation approved biopharmaceuticals are set to expire within the forecast period, which will lead to intense competition from generic drugs.

However, due to the economic crisis, major companies in the market have allocated minimal funds for the R&D of innovative drugs, which has hindered the development of new drugs and paved the way for the generic drugs market.

“Pharmaceutical companies developing generic drugs have enormous opportunities to capitalize on the market at this point in time,” says Faisal Ghaus, Vice President of TechNavio.

The new TechNavio report also emphasizes an increasing number of mergers and acquisitions, which will help vendors grow and expand their business. For a global company to enter the generic drugs market in Japan, it is important to form a partnership with a local manufacturer.

“In 2014, Teva acquired Taiyo Pharmaceutical, obtaining Taiyo Pharmaceutical’s portfolio of over 550 products. The company also gained access to Taiyo Pharmaceutical’s strong R&D team and local regulatory expertise,” says Ghaus.

Key Information Covered in the Report:

  • Market segmentation, size and forecast through 2019
  • Market Growth Drivers:
  • Market Challenges:
    • Intense Competition among Vendors
    • For a full detailed list, view our report.
  • Market Trends:
  • Key Vendors:
    • Meiji Seika Pharma Co. Ltd.
    • Nichi-Iko Pharmaceutical Co. Ltd.
    • Nipro Pharma Corp.
    • Sawai Pharmaceuticals Co. Ltd.
  • Other Prominent Vendors:
    • Actavis
    • Daiichi Sankyo
    • Daito Pharmaceutical
    • Eisai

TechNavio currently has more than 3000 market research reports on a huge range of topics, including 300+ reports on the pharmaceuticals market:

If you are interested in more information, please contact our media team at media@technavio.com.

CONTACT

TechNavio Research
Jes Ellacott
US: +1-630-333-9501
UK:
+44 208 123 1770
Media & Marketing Executive
www.technavio.com
media@technavio.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作